Sign Up
Stories
Ambrx Acquisition by Johnson & Johnson
Share
AB Science's Medical Breakthrough Webcas...
AEON Biopharma Advances Migraine Treatme...
Acquisition Progress Amid Safety Concern
ABBio Innovates Antibody Development
ABIONYX Pharma Files 2023 Document
AEON Biopharma Advances Migraine Treatme...
Overview
API
Ambrx Biopharma, Inc. shareholders endorse Johnson & Johnson's acquisition, securing $28.00 per share in cash, with the deal anticipated to finalize by March 7, 2024. Ambrx specializes in protein engineering and antibody drug conjugates for cancer therapy.
Ask a question
How could this acquisition impact the landscape of biopharmaceutical companies focusing on cancer therapies?
How might this acquisition enhance Johnson & Johnson's position in the cancer treatment market?
What potential innovations or developments could arise from the collaboration between Johnson & Johnson and Ambrx?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage